AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET
Company Participants
Tryn Stimart - Chief Legal & Compliance Officer
Carl Hansen - President, Chief Executive Officer
Andrew Booth - Chief Financial Officer
Conference Call Participants
Andrea Tan - Goldman Sachs
Jacqueline Kisa - TD Securities
Scott Schoenhaus - KeyBanc
Stephen Willey - Stifel
Operator
Good afternoon and welcome to AbCellera's Q1, 2024 Business Update Conference Call. My name is Harry and I will facilitate the audio portion of today's interactive broadcast. [Operator Instructions].
At this time, I would like to turn the call over to Tryn Stimart, AbCellera's Chief Legal and Compliance Officer. Please go ahead.
Tryn Stimart
Good morning. Good afternoon and good evening to everyone listening around the world. Thank you for joining us for AbCellera's 2024 first quarter earnings call. I'm Tryn Stimart, AbCellera's Chief Legal and Compliance Officer. Joining me on today's call are Dr. Carl Hansen, AbCellera's President and CEO and Andrew Booth, AbCellera's Chief Financial Officer.
During this call, we anticipate making projections and forward-looking statements based on our current expectations and pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995.
Our actual results could differ materially due to several factors as set forth in our latest form 10-K and subsequent forms 10-Q and 8-K filed with the Securities and Exchange Commission. AbCellera does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Our presentation today including our earnings press release issued earlier today and our SEC filings are available on our Investor Relations website. The information we provide about our pipeline is for the benefit of the investment community and is not intended to be promotional.
As we transition to our prepared remarks, please note that all dollars referred to during the call are in U.S. dollars. After our prepared remarks, we will open the lines for questions and answers.
Now, I'll turn the call over to Carl.
Carl Hansen
Thanks, Tryn, and thank you everyone for joining us today. As AbCellera continues to evolve into a clinical biotech company, we are directing our resources towards three main priorities.
Our first priority is advancing our internal pipeline, including ABCL635 and ABCL575. Both programs are in manufacturing and IND enabling studies and are on track for IND submissions in 2025.
Our second priority is completing platform investments that are focused on forward integration, including establishing our clinical manufacturing capabilities. We are on track to start our first engineering runs at our facility next year. And finally, our third priority is executing partnerships that we view as strategic to our long-term vision of becoming a scalable drug development company.